Skip to main
BNTX

BioNTech SE (BNTX) Stock Forecast & Price Target

BioNTech SE (BNTX) Analyst Ratings

Based on 11 analyst ratings
Buy
Strong Buy 55%
Buy 27%
Hold 18%
Sell 0%
Strong Sell 0%

Bulls say

BioNTech reported a robust cash position of approximately €16.7 billion at the end of Q3 2025, indicating strong financial stability and the capacity to fund ongoing research and development initiatives. The company's promising clinical pipeline, notably the global Phase 3 DYNASTY-Breast02 trial evaluating BNT323, suggests potential advancements in its oncology portfolio that could drive future revenue growth. Additionally, the development of an advanced COVID-19 vaccine that elicits improved immune responses against various sublineages reinforces BioNTech's commitment to innovation and addresses ongoing public health needs, positioning the company favorably in the biotechnology market.

Bears say

BioNTech faces significant financial challenges, including a projected full-year net loss per diluted share of €3.99 for 2025, following a net loss of €0.12 per diluted share for the third quarter of 2025. The company is also exposed to various risks that could hinder its performance, such as negative clinical trial data for several key oncology programs, slower-than-expected market uptake of its products, and potential regulatory and commercial issues. Furthermore, the ongoing volatility in the COVID-19 vaccine market, especially due to increased restrictions in the U.S., may divert investor attention from BioNTech's oncology initiatives, compounding the financial strain.

BioNTech SE (BNTX) has been analyzed by 11 analysts, with a consensus rating of Buy. 55% of analysts recommend a Strong Buy, 27% recommend Buy, 18% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of BioNTech SE and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About BioNTech SE (BNTX) Forecast

Analysts have given BioNTech SE (BNTX) a Buy based on their latest research and market trends.

According to 11 analysts, BioNTech SE (BNTX) has a Buy consensus rating as of Feb 17, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $140.31, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $140.31, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

BioNTech SE (BNTX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.